| abstract |
The present invention relates to a new pharmaceutical composition comprising idelalisib, or a salt or a prodrug or a solvate thereof, and pharmaceutically acceptable excipients, said excipients providing efficient idelalisib release from final dosage form in gastric and post-gastric conditions. The present invention relates to a new process for the preparation of pharmaceutical composition comprising idelalisib or a salt or a prodrug or a solvate thereof, or a salt, or a prodrug, or a solvate thereof. The pharmaceutical composition is particularly useful as a medicament, especially for the treatment of cancers of hematopoietic origin. |